Arvinas presented its clinical pipeline and strategic initiatives at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a focus on degrader programs and commercialization partnerships. The company's stock was trading at $8.68, down 0.97% from the previous close of $8.76, with a 52-week range of $6.97 to $14.51. The market capitalization stood at $567.55 million, with a beta of 1.76 and a fair value of $10.90 according to InvestingPro.
The company's cash runway extends into the second half of 2028, expected to fund all four clinical programs through key Phase I readouts. The balance sheet metrics include a current ratio of 7.91 and levered free cash flow of negative $208.8 million for the last twelve months as of Q2 2026.
Arvinas is commercializing VEPPANNU, a breast-cancer treatment, with Rigel as the commercialization partner. The partnership economics include upfront and near-term transition milestones of $85 million, additional downstream milestones of $320 million, and royalties in the mid-teens to mid-20s percentage range.
The company's pipeline includes ARV-393, a BCL-6 degrader for hematology and non-Hodgkin lymphoma, with initial Phase I safety, PK, and PD data in T-cell lymphoma expected by year-end 2024. More complete data, including more LBCL patients and combination data, is expected in mid-2025. Benchmarks noted include a 54% response rate for a BCL-6 degrader in diffuse large B-cell lymphoma (DLBCL) and a realistic response rate benchmark for second-line AITL in the upper 30% to low 40% range.
LRRK2-102, a degrader for neurodegeneration, including Parkinson's and PSP, is expected to present new biomarker data at the MDS conference in Korea within one month of the talk. The Phase I-B study timeline was pushed out to 2027 following regulatory requests for chronic toxicology data.
ARV-027, an androgen receptor degrader for Kennedy's disease and SBMA, began Phase I clinical dosing in early 2024 and is expected to present first Phase I data in the first half of 2025. ARV-6723, a degrader in immuno-oncology, has recently entered the clinic. The KRAS G12D degrader program will only move forward with a partner, not as a standalone Arvinas program.
CEO Randy stated, "We've got a demonstrated ability to move programs into the clinic, thanks to Angela and her team. Now the question is, which of those are we going to wholly own and move forward?" CSO Angela emphasized the importance of PROTACs in removing drivers of certain subtypes of non-Hodgkin lymphoma and the potential of LRRK2 degradation in neurodegeneration.
